XB002: Model-Based Dose Selection for a Novel Anti-Tissue Factor ADC With a ZLA Payload for the Treatment of Solid Tumours

Time: 11:45 am
day: Track B - Day 1 - AM


  • Review how efficacy data from Pharmacology tumour models in mice and PK data from monkeys were used to predict XB002 human PK and estimate human efficacious dose
  • Understand how nonclinical safety in cynomolgus monkeys demonstrated adequate safety margins for the range of doses explored in the FTIH study
  • Assess how the PK model was fitted to the human PK from the FTIH dose escalation phase to refine dose predictions